While it might not have been making it headline, the pharmaceutical sector or commonly called as pharma has come through a tough period due to US FDA and other factors. It has been witnessing a turnaround of sorts which has been slow but more companies are showing improvement in their performance. Also there is a process of re-rating which is quietly going on in the sector. It was large players which got the attention of tend to gain first and then it is smaller and mid sized. If one looks at the corporate announcement about approval of drugs by the US FDA or other drug regulator or any entry into new markets, a number of them are coming from mid and small companies. Given the lesson which the Indian pharma industry has learnt after its reckless approach between 2005 to 2015, there is a high probability that the sector may gain attention.
